Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Long-Term Investments (2024 - 2025)

Sagimet Biosciences' Long-Term Investments history spans 2 years, with the latest figure at $8.8 million for Q3 2025.

  • Quarterly Long-Term Investments fell 49.6% to $8.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $8.8 million through Sep 2025, down 49.6% year-over-year, with the annual reading at $7.4 million for FY2024, N/A changed from the prior year.
  • Long-Term Investments came in at $8.8 million for Q3 2025, down from $10.1 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $22.1 million in Q2 2024 to a low of $7.4 million in Q4 2024.